Indian vaccine innovation: the case of Shantha Biotechnics

BACKGROUND: Although the World Health Organization had recommended that every child be vaccinated for Hepatitis B by the early 1980s, large multinational pharmaceutical companies held monopolies on the recombinant Hepatitis B vaccine. At a price as high as USD$23 a dose, most Indians families could...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakma, Justin, Masum, Hassan, Perampaladas, Kumar, Heys, Jennifer, Singer, Peter A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110116/
https://www.ncbi.nlm.nih.gov/pubmed/21507259
http://dx.doi.org/10.1186/1744-8603-7-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110116/
https://www.ncbi.nlm.nih.gov/pubmed/21507259
http://dx.doi.org/10.1186/1744-8603-7-9

Ejemplares similares